Literature DB >> 55599

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.

C D Marsden, J D Parkes.   

Abstract

Fluctuations in performance in patients with Parkinson's disease on chronic levodopa therapy (the "on-off" effect) are due to several factors. The increasing severity during treatment of early morning akinesia, "freezing" episodes, and end-of-dose deterioration are probably due to progression of the underlying disease. Peak-dose dyskinesia and peak-dose akinesia are due to levodopa over dosage. "Yo-yo-ing", which is the severest form of such fluctuation in mobility and dyskinesias, may represent the sum of these disorders.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 55599     DOI： 10.1016/s0140-6736(76)91416-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  110 in total

1.  Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease.

Authors:  C S Palmer; J K Schmier; E Snyder; B Scott
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

Review 2.  Bromocriptine for levodopa-induced motor complications in Parkinson's disease.

Authors:  J J van Hilten; C Ramaker; W J Van de Beek; M J Finken
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 3.  Emerging therapies in the pharmacological treatment of Parkinson's disease.

Authors:  Amos D Korczyn; Miri Nussbaum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 5.  Parkinson's disease.

Authors:  C D Marsden
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

6.  The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers.

Authors:  D R Robertson; I Higginson; B S Macklin; A G Renwick; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

7.  Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.

Authors:  Mark Johnson; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2012-06-13       Impact factor: 7.446

Review 8.  Continuous drug delivery in Parkinson's disease.

Authors:  Marina Senek; Dag Nyholm
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 9.  Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

10.  Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease.

Authors:  Gwenn S Smith; Kelly A Mills; Greg M Pontone; W Stanley Anderson; Kate M Perepezko; James Brasic; Yun Zhou; Jason Brandt; Christopher R Butson; Daniel P Holt; William B Mathews; Robert F Dannals; Dean F Wong; Zoltan Mari
Journal:  Parkinsonism Relat Disord       Date:  2019-04-16       Impact factor: 4.891
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.